Progyny (NASDAQ:PGNY) CFO Mark Livingston Sells 2,139 Shares of Company Stock

Progyny, Inc. (NASDAQ:PGNY) CFO Mark Livingston sold 2,139 shares of the company’s stock in a transaction on Wednesday, November 4th. The stock was sold at an average price of $30.00, for a total transaction of $64,170.00. Following the completion of the transaction, the chief financial officer owned 70,314 shares of the company’s stock, valued at $2,109,420. This trade represents a 2.95% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Progyny Stock Performance

PGNY traded up $0.47 during trading on Friday, reaching $34.84. The stock had a trading volume of 1,548,505 shares, compared to its average volume of 956,940. The stock has a market cap of $2.67 billion, a PE ratio of 31.96, a PEG ratio of 2.03 and a beta of 0.97. The business has a 50-day moving average of $27.45 and a 200-day moving average of $24.59. Progyny, Inc. has a one year low of $16.10 and a one year high of $35.50.

Progyny (NASDAQ:PGNY) last released its earnings results on Wednesday, November 4th. The company reported $0.52 earnings per share for the quarter, topping analysts’ consensus estimates of $0.31 by $0.21. The company had revenue of $341.25 million during the quarter, compared to the consensus estimate of $340.76 million. Progyny had a return on equity of 15.98% and a net margin of 6.00%. Progyny’s quarterly revenue was up 8.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.15 EPS. Equities research analysts forecast that Progyny, Inc. will post 1.25 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of PGNY. Bank of America Corp DE purchased a new position in shares of Progyny during the second quarter valued at approximately $17,264,000. Hsbc Holdings PLC bought a new position in shares of Progyny during the second quarter valued at approximately $760,000. AWM Investment Company Inc. bought a new position in shares of Progyny during the second quarter valued at approximately $6,343,000. Corient Private Wealth LP bought a new position in shares of Progyny during the second quarter valued at approximately $3,488,000. Finally, Squarepoint Ops LLC purchased a new stake in Progyny in the second quarter worth $1,705,000. Institutional investors own 94.93% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the company. Jefferies Financial Group set a $33.00 target price on Progyny in a research note on Tuesday, September 8th. BTIG Research raised their price target on Progyny from $30.00 to $40.00 and gave the stock a “buy” rating in a research report on Friday, July 24th. Cantor Fitzgerald lifted their price target on Progyny from $31.00 to $35.00 and gave the stock an “overweight” rating in a research note on Thursday. Canaccord Genuity Group set a $35.00 price objective on Progyny in a research report on Friday, August 7th. Finally, Citizens Jmp increased their price objective on Progyny from $33.00 to $38.00 and gave the company a “market outperform” rating in a research note on Thursday. Eleven investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $34.92.

Progyny News Summary

Here are the key news stories impacting Progyny this week:

• Positive Sentiment: Progyny reported third-quarter earnings of $0.52 per share and revenue of $341.25 million, slightly above the cited consensus revenue estimate. Revenue grew 8.9% year over year, while earnings increased from $0.15 per share a year earlier. Read More.
• Positive Sentiment: The company raised its full-year 2026 earnings guidance, a sign that management sees stronger earnings prospects. Read More.
• Positive Sentiment: Several analysts raised their price targets following the results: Citizens JMP and Leerink Partners moved to $38, while Cantor Fitzgerald raised its target to $35 and maintained an overweight rating. These revisions reinforce a favorable analyst view, although the targets imply varying degrees of potential upside. Read More.
• Neutral Sentiment: Coverage highlighted new client wins and margin expansion, but also noted a cautious market response. This suggests investors may be weighing growth and profitability improvements against expectations already reflected in the stock. Read More.

About Progyny

Progyny, Inc is a benefits-management company focused on fertility and family-building care. The company works with employers to provide comprehensive benefits that help members access fertility treatments and related services through a network of specialized providers.

Its offerings include coverage and support for services such as in vitro fertilization, fertility testing, egg and sperm freezing, donor services, gestational surrogacy, and adoption. Progyny also provides pharmacy benefits through Progyny Rx, as well as personalized guidance intended to help members navigate treatment options, providers, and the broader family-building process.

Progyny primarily serves self-insured employers and their employees in the United States.